期刊
BIOSENSORS-BASEL
卷 12, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/bios12090728
关键词
lateral flow immunoassay; biosensors; COVID-19; SARS-CoV-2; diagnosis; antibodies
资金
- PRODEP (Programa para el Desarrollo Profesional Docente en Educacion Superior)
- Universidad Autonoma del Estado de Hidalgo and Consejo Nacional de Ciencia y Tecnologia (CONACyT)
This review summarizes the advantages, limitations, and evolution of lateral flow immunoassays (LFIA) during the SARS-CoV-2 pandemic and the challenges of improving these diagnostic devices.
SARS-CoV-2 is an emerging infectious disease of zoonotic origin that caused the coronavirus disease in late 2019 and triggered a pandemic that has severely affected human health and caused millions of deaths. Early and massive diagnosis of SARS-CoV-2 infected patients is the key to preventing the spread of the virus and controlling the outbreak. Lateral flow immunoassays (LFIA) are the simplest biosensors. These devices are clinical diagnostic tools that can detect various analytes, including viruses and antibodies, with high sensitivity and specificity. This review summarizes the advantages, limitations, and evolution of LFIA during the SARS-CoV-2 pandemic and the challenges of improving these diagnostic devices.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据